KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2016 - 2025)

Vertex Pharmaceuticals has reported Total Non-Current Liabilities over the past 17 years, most recently at $5.7 billion for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $5.7 billion for Q4 2025, up 11.72% from a year ago — trailing twelve months through Dec 2025 was $5.7 billion (up 11.72% YoY), and the annual figure for FY2025 was $5.7 billion, up 11.72%.
  • Total Non-Current Liabilities for Q4 2025 was $5.7 billion at Vertex Pharmaceuticals, down from $6.3 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for VRTX hit a ceiling of $6.3 billion in Q3 2025 and a floor of $2.9 billion in Q3 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $4.2 billion (2023), compared with a mean of $4.3 billion.
  • Peak annual rise in Total Non-Current Liabilities hit 31.08% in 2021, while the deepest fall reached 2.67% in 2021.
  • Vertex Pharmaceuticals' Total Non-Current Liabilities stood at $3.0 billion in 2021, then rose by 17.27% to $3.6 billion in 2022, then grew by 20.26% to $4.3 billion in 2023, then grew by 19.59% to $5.1 billion in 2024, then rose by 11.72% to $5.7 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $5.7 billion (Q4 2025), $6.3 billion (Q3 2025), and $5.7 billion (Q2 2025) per Business Quant data.